TABLE 1 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 BELOW PROVIDED ARE THE ALTERNATIVE CHEMOTHERAPIES OF CAR-T CELL THERAPY:
TABLE 3 TOTAL HEALTH SPENDING BY THE U.S. (2015-2016)
TABLE 4 EUROPE CAR-T CELL THERAPY TREATMENTMARKET, BY MOLECULE, 2019-2028 (USD MILLION)
TABLE 5 EUROPE AUTOLOGOUS CAR-T CELLS IN CAR-T CELL THERAPY TREATMENTMARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 6 EUROPE ALLOGENEIC CAR-T CELLS IN CAR-T CELL THERAPY TREATMENTMARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 EUROPE CAR-T CELL THERAPY TREATMENTMARKET, BY STRUCTURE, 2019-2028 (USD MILLION)
CELYAD IS ENGAGED IN THE MANUFACTURING OF CYAD-211, A FIRST GENERATION CAR-T CELL THERAPY EXPRESSING BCMA TARGETING CHIMERIC ANTIGEN RECEPTOR WHICH INTERFERES WITH THE EXPRESSION OF THE CD3Ζ OF T CELL RECEPTOR COMPLEX.
TABLE 8 EUROPE FIRST GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 EUROPE SECOND GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 EUROPE THIRD GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 EUROPE THIRD GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 EUROPE CAR-T CELL THERAPY TREATMENTMARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 13 EUROPE ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 EUROPE ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY ANTIGENS ON HEMATOLOGIC MALIGNANCIES, 2019-2028 (USD MILLION)
TABLE 15 EUROPE ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENTMARKET , BY REGION, 2017-2028 (USD MILLION)
TABLE 16 EUROPE ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY ANTIGENS ON SOLID TUMORS, 2019-2028 (USD MILLION)
TABLE 17 EUROPE OTHERS IN CAR-T CELL THERAPY TREATMENTMARKET , BY REGION, 2017-2028 (USD MILLION)
TABLE 18 EUROPE YESCARTA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 19 EUROPE YESCARTA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 20 EUROPE KYMRIAH IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 21 EUROPE TECARTUS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 22 EUROPE OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 23 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 24 EUROPE FOLLICULAR LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2017-2028 (USD MILLION)
TABLE 25 EUROPE DIFFUSE LARGE B-CELL LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 26 EUROPE ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 27 EUROPE MANTLE CELL LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 28 EUROPE MULTIPLE MYELOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 29 EUROPE HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 30 EUROPE HEMATOLOGIC MALIGNANCIES ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 31 EUROPE LUNG CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 32 EUROPE CHRONIC LYMPHOCYTIC LEUKEMIA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 33 EUROPE GASTRIC CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 34 EUROPE PANCREATIC CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 35 EUROPE BREAST CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 36 EUROPE OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 37 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 38 EUROPE HOSPITALS IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2017-2028 (USD MILLION)
TABLE 39 EUROPE SPECIALTY CLINICS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 40 EUROPE OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 41 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 42 EUROPE HOSPITAL PHARMACY IN CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2028 (USD MILLION)
TABLE 43 EUROPE OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 44 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 46 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 47 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 48 EUROPE ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 49 EUROPE ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 50 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 51 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 52 EUROPE HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 53 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 54 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 55 GERMANY CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 56 GERMANY CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 57 GERMANY CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 58 GERMANY ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 59 GERMANY ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 60 GERMANY CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 61 GERMANY CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 62 GERMANY HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 63 GERMANY CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 64 GERMANY CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 65 U.K CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 66 U.K CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 67 U.K CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 68 U.K ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 69 U.K ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 70 U.K CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 71 U.K CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 72 U.K HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 73 U.K CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 74 U.K CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 75 FRANCE CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 76 FRANCE CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 77 FRANCE CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 78 FRANCE ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 79 FRANCE ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 80 FRANCE CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 81 FRANCE CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 82 FRANCE HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 83 FRANCE CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 84 FRANCE CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 85 ITALY CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 86 ITALY CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 87 ITALY CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 88 ITALY ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 89 ITALY ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 90 ITALY CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 91 ITALY CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 92 ITALY HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 93 ITALY CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 94 ITALY CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 95 SPAIN CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 96 SPAIN CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 97 SPAIN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 98 SPAIN ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 99 SPAIN ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 100 SPAIN CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 101 SPAIN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 102 SPAIN HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 103 SPAIN CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 104 SPAIN CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 105 NETHERLANDS CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 106 NETHERLANDS CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 107 NETHERLANDS CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 108 NETHERLANDS ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 109 NETHERLANDS ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 110 NETHERLANDS CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 111 NETHERLANDS CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 112 NETHERLANDS HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 113 NETHERLANDS CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 114 NETHERLANDS CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 115 RUSSIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 116 RUSSIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 117 RUSSIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 118 RUSSIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 119 RUSSIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 120 RUSSIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 121 RUSSIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 122 RUSSIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 123 RUSSIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 124 RUSSIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 125 SWITZERLAND CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 126 SWITZERLAND CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 127 SWITZERLAND CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 128 SWITZERLAND ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 129 SWITZERLAND ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 130 SWITZERLAND CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 131 SWITZERLAND CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 132 SWITZERLAND HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 133 SWITZERLAND CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 134 SWITZERLAND CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 135 BELGIUM CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 136 BELGIUM CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 137 BELGIUM CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 138 BELGIUM ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 139 BELGIUM ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 140 BELGIUM CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 141 BELGIUM CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 142 BELGIUM HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 143 BELGIUM CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 144 BELGIUM CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 145 TURKEY CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 146 TURKEY CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 147 TURKEY CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 148 TURKEY ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 149 TURKEY ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 150 TURKEY CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 151 TURKEY CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 152 TURKEY HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 153 TURKEY CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 154 TURKEY CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 155 AUSTRIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 156 AUSTRIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 157 AUSTRIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 158 AUSTRIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 159 AUSTRIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 160 AUSTRIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 161 AUSTRIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 162 AUSTRIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 163 AUSTRIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 164 AUSTRIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 165 NORWAY CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 166 NORWAY CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 167 NORWAY CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 168 NORWAY ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 169 NORWAY ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 170 NORWAY CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 171 NORWAY CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 172 NORWAY HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 173 NORWAY CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 174 NORWAY CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 175 HUNGARY CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 176 HUNGARY CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 177 HUNGARY CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 178 HUNGARY ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 179 HUNGARY ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 180 HUNGARY CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 181 HUNGARY CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 182 HUNGARY HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 183 HUNGARY CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 184 HUNGARY CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 185 LITHUANIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 186 LITHUANIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 187 LITHUANIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 188 LITHUANIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 189 LITHUANIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 190 LITHUANIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 191 LITHUANIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 192 LITHUANIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 193 LITHUANIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 194 LITHUANIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 195 IRELAND CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 196 IRELAND CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 197 IRELAND CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 198 IRELAND ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 199 IRELAND ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 200 IRELAND CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 201 IRELAND CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 202 IRELAND HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 203 IRELAND CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 204 IRELAND CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 205 POLAND CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 206 POLAND CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 207 POLAND CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 208 POLAND ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 209 POLAND ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 210 POLAND CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 211 POLAND CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 212 POLAND HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 213 POLAND CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 214 POLAND CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 215 REST OF EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)